Cargando…
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis
BACKGROUND: Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanz...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449274/ https://www.ncbi.nlm.nih.gov/pubmed/30883017 http://dx.doi.org/10.1111/1759-7714.13030 |
_version_ | 1783408807942029312 |
---|---|
author | Wang, Mopei Liang, Li Lu, Jiaxiong Yu, Yang Zhao, Yanling Shi, Zhenfeng Li, Hui Xu, Xin Yan, Yuxian Niu, Yan Liu, Zhentao Shen, Lin Zhang, Hong |
author_facet | Wang, Mopei Liang, Li Lu, Jiaxiong Yu, Yang Zhao, Yanling Shi, Zhenfeng Li, Hui Xu, Xin Yan, Yuxian Niu, Yan Liu, Zhentao Shen, Lin Zhang, Hong |
author_sort | Wang, Mopei |
collection | PubMed |
description | BACKGROUND: Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanzomib has antitumor effects and synergizes with doxorubicin (Dox) in human breast cancer cell lines. METHODS: Cell proliferation assay and flow cytometry were used to evaluate cell viability and apoptosis in eight human breast cancer cell lines after treatment with delanzomib or Dox. Essential molecules of the p53, MAPK, and apoptosis signaling pathways were analyzed by Western blotting. RESULTS: Delanzomib induced cell death and demonstrated synergism with Dox in all tested breast cancer cell lines. In addition, delanzomib enhanced the Dox‐induced phosphorylation of p38/JNK and the expression of transcriptional target proteins of p53, such as p21, p27, NOXA, and PUMA. CONCLUSION: The combined regimen of the proteasome inhibitor delanzomib with Dox chemotherapy may become an effective strategy for breast cancer therapy. |
format | Online Article Text |
id | pubmed-6449274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-64492742019-04-15 Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis Wang, Mopei Liang, Li Lu, Jiaxiong Yu, Yang Zhao, Yanling Shi, Zhenfeng Li, Hui Xu, Xin Yan, Yuxian Niu, Yan Liu, Zhentao Shen, Lin Zhang, Hong Thorac Cancer Original Articles BACKGROUND: Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanzomib has antitumor effects and synergizes with doxorubicin (Dox) in human breast cancer cell lines. METHODS: Cell proliferation assay and flow cytometry were used to evaluate cell viability and apoptosis in eight human breast cancer cell lines after treatment with delanzomib or Dox. Essential molecules of the p53, MAPK, and apoptosis signaling pathways were analyzed by Western blotting. RESULTS: Delanzomib induced cell death and demonstrated synergism with Dox in all tested breast cancer cell lines. In addition, delanzomib enhanced the Dox‐induced phosphorylation of p38/JNK and the expression of transcriptional target proteins of p53, such as p21, p27, NOXA, and PUMA. CONCLUSION: The combined regimen of the proteasome inhibitor delanzomib with Dox chemotherapy may become an effective strategy for breast cancer therapy. John Wiley & Sons Australia, Ltd 2019-03-18 2019-04 /pmc/articles/PMC6449274/ /pubmed/30883017 http://dx.doi.org/10.1111/1759-7714.13030 Text en © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Wang, Mopei Liang, Li Lu, Jiaxiong Yu, Yang Zhao, Yanling Shi, Zhenfeng Li, Hui Xu, Xin Yan, Yuxian Niu, Yan Liu, Zhentao Shen, Lin Zhang, Hong Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis |
title | Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis |
title_full | Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis |
title_fullStr | Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis |
title_full_unstemmed | Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis |
title_short | Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis |
title_sort | delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449274/ https://www.ncbi.nlm.nih.gov/pubmed/30883017 http://dx.doi.org/10.1111/1759-7714.13030 |
work_keys_str_mv | AT wangmopei delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT liangli delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT lujiaxiong delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT yuyang delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT zhaoyanling delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT shizhenfeng delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT lihui delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT xuxin delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT yanyuxian delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT niuyan delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT liuzhentao delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT shenlin delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis AT zhanghong delanzomibanovelproteasomeinhibitorsensitizesbreastcancercellstodoxorubicininducedapoptosis |